Imatinib resistant BCR-ABL1 mutations at relapse in children with Ph+ ALL: a Children's Oncology Group (COG) study. Br J Haematol 2012 May;157(4):507-10
Date
02/04/2012Pubmed ID
22299775Pubmed Central ID
PMC4290865DOI
10.1111/j.1365-2141.2012.09039.xScopus ID
2-s2.0-84859970467 (requires institutional sign-in at Scopus site) 39 CitationsAuthor List
Chang BH, Willis SG, Stork L, Hunger SP, Carroll WL, Camitta BM, Winick NJ, Druker BJ, Schultz KRAuthor
Bruce m. Camitta Professor in the Pediatrics department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdolescentAdult
Antineoplastic Agents
Base Sequence
Benzamides
Child
Child, Preschool
Drug Resistance, Neoplasm
Fusion Proteins, bcr-abl
Humans
Imatinib Mesylate
Infant
Male
Mutation
Philadelphia Chromosome
Piperazines
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Pyrimidines
Recurrence
Young Adult
